Is this you?
Request access for University Gastroenterology with your @universitygi.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
University Gastroenterology
Unclaimed profileSite Network · Southern New England (RI and MA based) · ~6 sites
Intera lens
ICP 4Lift (cardio sample) 0.47Recruit soph 0.14
Quality Scorecard (1–100)
Overall83Recruit56Ops90Sponsor98Ther95
Performance (observed)
Historical trials
800
Completed
386
Terminated/Withdrawn
93
Completion rate
81%
Active now
218
Phase 2
246
Phase 3
224
Realized enrollment
367,073
First study year
1997
Years active
29
Match confidence
low (approx)
Enrollment velocity (inf)
12,658
Therapeutic
Areas
Gastroenterology: IBD (Crohn's disease, ulcerative colitis), NASH, hepatology, anorectal conditions, general GI
Specialties
Gastroenterology, GI conditions, hepatology
Breadth (conditions)
1,186
Languages
English + Spanish (detected)
States
RI, MA (Southern New England region)
Recruitment (web observed)
Advertises recruitment
Yes
Capability notes
Clinical research division with active trial participation. Part of GI Alliance research network. SPARC IBD site status. Ongoing clinical trial enrollment visible.
Relationships
Sponsors
National Cancer Institute (NCI); Shandong University; Gilead Sciences; Alliance for Clinical Trials in Oncology; AbbVie; Pfizer
CROs
Colitis-Crohn Foreningen; Crohn's and Colitis Foundation; ICON Clinical Research; IQVIA Commercial GmbH & Co. OHG; PPD, Part of Thermo Fisher Scientific; PRA Health Sciences
Owner / parent
Partnership with GI Alliance
Expansion
Multiple locations in RI and MA
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Lisa Mueller, MD (Medical Co-Director); Jason Ferreira, MD (Medical Co-Director)
VP Site Ops
Unknown
VP Recruitment
Unknown
Tech & DCT
eSource
Yes
Builds tech
Vendors
Tech stack
Advanced GI procedures (capsule endoscopy, ERCP, EUS, FibroScan), partnership with GI Alliance research infrastructure
Recruiting visible
Y
Notes
Small regional private practice (6 sites, New England only) with research division partnered under GI Alliance. Geographic limitation and modest size reduce recruitment scaling potential. Integrated into larger GI Alliance network rather than independent operator. Limited standalone growth trajectory for Intera partnership. [Validated: 4 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 0.55Liftability 0.47Overall83
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.